Goldstein S, Bates ER, Bhatt DL. , et al; AXIOM Investigators. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thromb Haemost 2014; 111 (06) 1141-1152
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.